Abstract
Objective: To investigate the association between the use of fluoroquinolone agents and the risk of tendinitis in a large population-based case-control study.
Methods: The study was performed by linking automated health databases from the Region of Lombardia, Italy. Cases were patients aged ≥18 years who had a hospital discharge diagnosis of non-traumatic tendinitis in 2002–3. For each case, up to five controls were randomly selected among those eligible for inclusion in the study. A conditional logistic regression model was used to estimate the odds ratio of tendinitis associated with the current, recent and past use of fluoroquinolones. Odds ratios were adjusted for exposure to other antibacterials and other drugs.
Results: 22 194 cases and 104 906 controls met the inclusion criteria. Current use of fluoroquinolones significantly increased the risk of tendon disorders as a whole (odds ratio [OR] = 1.7; 95% CI 1.4, 2.0), tendon rupture (OR = 1.3; 95% CI 1.0, 1.8) and rupture of the Achilles’ tendon (OR = 4.1; 95% CI 1.8, 9.6). Concomitant use of corticosteroids and fluoroquinolones increased the risk of both tendon rupture (OR = 3.1; 95% CI 1.5, 6.3) and rupture of the Achilles’ tendon (OR = 43.2; 95% CI 5.5, 341.1).
Discussion: Evidence that exposure to fluoroquinolones is associated with the sudden occurrence of tendinitis is supported by this large population-based study. We can estimate that a single case of rupture of the Achilles’ tendon would occur for every 5958 persons treated with fluoroquinolones (95% CI 2148, 23 085). The corresponding number needed to harm is 979 (95% CI 122, 9172) for patients who concomitantly use corticosteroids and 1638 (95% CI 351, 8843) for those aged >60 years.
Conclusion: Clinicians should be aware of this adverse effect, and the increased risk for fluoroquinolone-associated tendinitis in elderly patients with corticosteroid use must be considered when these agents are prescribed.
Similar content being viewed by others
References
Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. N Engl J Med 1991; 324: 384–94
Lietman PS. Fluoroquinolone toxicities: an update. Drugs 1995; 49Suppl. 2: 159–63
Ball P, Mandell L, Niki Y, et al. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf 1999; 21: 407–21
Bailey RR, Kirk JA, Peddie BA. Norfloxacin induced rheumatic disease [letter]. N Z Med J 1983; 96: 590
McEwan SR, Davey PG. Ciprofloxacin and tenosynovitis [letter]. Lancet 1988; II: 900
Franck JL, Bouteiller G, Chagnaud P, et al. Rupture des tendons d’Achille chez deux adultes traites par pefloxacine dont un cas bilateral. Rev Rhum Mal Osteoartic 1991; 58: 904
Huston KA. Achilles tendinitis and tendon rupture due to fluoroquinolone antibiotics [letter]. N Engl J Med 1994; 331: 748
Le Huec JC, Schaeverbeke T, Chauveaux D, et al. Epicondylitis after treatment with fluoroquinolone antibiotics. J Bone Joint Surg Br 1995; 77: 293–5
McGarvey WC, Singh D, Trevino SG. Partial Achilles tendon ruptures associated with fluoroquinolone antibiotics: a case report and literature review. Foot Ankle Int 1996; 17: 496–8
Pierfitte C, Royer RJ. Tendon disorders with fluoroquinolones. Therapie 1996; 51: 419–20
Movin T, Gad A, Guntner P, et al. Pathology of the Achilles tendon in association with ciprofloxacin treatment. Foot Ankle Int 1997; 18: 297–9
West MB, Gow P. Ciprofloxacin, bilateral Achilles tendonitis and unilateral tendon rupture. N Z Med J 1998; 111: 18–9
Gold L, Igra H. Levofloxacin-induced tendon rupture: a case report and review of the literature. J Fam Pract 2003; 16: 458–60
Davey PG, Bax RP, Newey J, et al. Growth in the use of antibiotics in the community in England and Scotland in 1980-93. BMJ 1996; 312: 613
Bremon AR, Ruiz-Tovar M, Gorricho BP, et al. Non-hospital consumption of antibiotics in Spain: 1987-1997. J Antimicrob Chemother 2000; 45: 395–400
Van der Linden PD, Nab HW, Simonian S, et al. Fluoroquinolone use and the change in incidence of tendon rupture in the Netherlands. Pharm World Sci 2001; 23: 89–92
Royer RJ, Pierfitte C, Netter P. Features of tendon disorders with fluoroquinolones. Therapie 1994; 49: 75–6
Pierfitte C, Gillet P, Royer RJ. More on fluoroquinolone antibiotics and tendon rupture [letter]. N Engl J Med 1995; 332: 193
Ribard P, Audisio F, Kahan MF, et al. Seven Achilles tendinitis including 3 complicated by rupture during fluoroquinolone therapy. J Rheumatol 1992; 19: 1479–81
Meyboom RH, Olsson S, Knol A, et al. Achilles tendinitis induced by pefloxacin and other fluoroquinolone derivatives. Pharmacoepidemiol Drug Saf 1994; 3: 185–9
Zabraniecki L, Negrier I, Vergne P, et al. Fluoroquinolone induced tendinopathy: report of 6 cases. J Rheumatol 1996; 23: 516–20
Van der Linden PD, Puijenbroek EPV, Feenstra J, et al. Tendon disorders attributed to fluoroquinolones: a study on 42 spontaneous reports in the period 1988 to 1998. Arthritis Care Res 2001; 45: 235–9
Leone R, Venegoni M, Motola D, et al. Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three Italian Regions. Drug Saf 2003; 26: 109–20
Donck JB, Segaert MF, Vanrenterghem YF. Fluoroquinolones and Achilles tendinopathy in renal transplant recipients. Transplantation 1994; 58: 736–7
Melhus A. Fluoroquinolones and tendon disorders. Expert Opin Drug Saf 2005; 4: 299–309
Szarfman A, Chen M, Blum MD. More on fluoroquinolone antibiotics and tendon rupture [letter]. N Engl J Med 1995; 332: 193
Committee on Safety of Medicines. Tendon damage associated with quinolone antibiotics. Curr Probl Pharmacovigilance 1995; 21: 8
ADRAC. Tendinitis and tendon rupture with fluoroquinolones. Aust Adv Drug React Bull 1999; 18: 10
Stahlmann R, Lode H. Toxicity of quinolones. Drugs 1999; 58Suppl. 2: 37–42
Shakibaei M, de Souza P, van Sickle D, et al. Biochemical changes in Achilles tendon from juvenile dogs after treatment with ciprofloxacin or feeding a magnesium-deficient diet. Arch Toxicol 2001; 75: 369–74
Shakibaei M, Stahlmann R. Ultrastructure of Achilles tendon from rats after treatment with fleroxacin. Arch Toxicol 2001; 75: 97–102
Sendzik J, Shakibaei M, Schafer-Korting M, et al. Fluoroquinolones cause changes in extracellular matrix, signalling proteins, metalloproteinases and caspase-3 in cultured human tendon cells. Toxicology 2005; 212: 24–36
Van der Linden PD, van de Lei J, Nab HW, et al. Achilles tendinitis associated with fluoroquinolones. Br J Clin Pharmacol 1999; 48: 433–7
Van der Linden PD, Sturkenboom MC, Herings RM, et al. Fluoroquinolones and risk of Achilles tendon disorders: a case-control study. BMJ 2002; 324: 1306–7
Van der Linden PD, Sturkenboom MC, Herings RM, et al. Increased risk of Achilles tendon rupture with quinolone antibacterial use, especially in the elderly patients taking oral corticosteroids. Arch Intern Med 2003; 163: 1801–7
Seeger JD, West WA, Fife D, et al. Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population. Pharmacoepidemiol Drug Saf. Epub 2006 Feb 3
Breslow NE, Day NE. Statistical methods in cancer research. Vol. I. The analysis of case-control studies. IARC Scientific Publications no. 32. Lyon: International Agency for Research on Cancer, 1980
Leppilahti J, Puranen J, Orava S. Incidence of Achilles tendon rupture. Acta Orthop Scand 1996; 67: 277–9
Leppilahti J, Orava S. Total Achilles tendon rupture: a review. Sports Med 1998; 25: 79–100
Maffulli N. Rupture of Achilles tendon. J Bone Joint Surg Br 1999; 81-A(7): 1019–36
Waterston SW, Maffulli N, Ewen SW. Subcutaneous rupture of the Achilles tendon: basic science and some aspects of clinical practice. Br J Sports Med 1997; 31: 285–98
Leufkens HG, Urquhart J. Variability in patterns of drug usage. J Pharm Pharmacol 1994; 46: 433–7
Copeland KT, Checkoway H, McMichael AJ, et al. Bias due to misclassification in the estimation of relative risk. Am J Epidemiol 1977; 105: 488–95
Wilton LV, Pearce GL, Mann RD. A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin and cefixime examined by observational cohort studies. Br J Clin Pharmacol 1996; 41: 277–84
Gravlee JR, Hatch RL, Galea AM. Achilles tendon rupture: a challenging diagnosis. J Am Board Farm Pract 2000; 13: 371–3
Rask MR. Achilles tendon rupture owing to rheumatoid disease: case-report with a nine-year follow-up. JAMA 1978; 239: 435–6
Ford LT, DeBender L. Tendon rupture after local steroid injection. South Med J 1979; 72: 827–30
Kleinman M, Gross AE. Achilles tendon rupture following steroid injection: report of three cases. J Bone Joint Surg Am 1983; 65: 1345–7
Dikey W, Patterson V. Bilateral Achilles tendon rupture simulating peripheral neuropathy: unusual complication of steroid therapy. J R Soc Med 1987; 80: 386–7
Newnham DM, Douglas JG, Legge JS, et al. Achilles tendon rupture: an underrated complication of corticosteroid treatment. Thorax 1991; 46: 853–4
Hersh BL, Heath NS. Achilles tendon rupture as a result of oral steroid therapy. J Am Podiatr Med Assoc 2002; 92: 355–8
Bjerre LM, LeLorier J. Expressing the magnitude of adverse effects in case-control studies: “the number of patients needed to be treated for one additional patient to be harmed”. BMJ 2000; 320: 503–6
Acknowledgments
Support for this study came from grants from the Italian Minister of the University and Research (“Fondo d’Ateneo per la Ricerca” portion, year 2005, and PRIN portion, protocol no. 2005068001, year 2005). The authors have no conflicts of interest that are directly relevant to the content of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Corrao, G., Zambon, A., Bertù, L. et al. Evidence of Tendinitis Provoked by Fluoroquinolone Treatment. Drug-Safety 29, 889–896 (2006). https://doi.org/10.2165/00002018-200629100-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-200629100-00006